FDA Approves DULOXETINE DELAYED-RELEASE — Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceutical, Inc. has secured a new FDA approval for the generics of Duloxetine Hydrochloride, a revenue-generating asset that is set to bolster the company’s portfolio as it maintains a dominant market share within the widely prescribed oral antidepressant and neuropathic pain drug class.